Adrian M. Jones - 24 Mar 2020 Form 4 Insider Report for T2 Biosystems, Inc. (TTOO)

Role
Director
Signature
/s/ Jamison Yardley, Attorney-in-fact
Issuer symbol
TTOO
Transactions as of
24 Mar 2020
Transactions value $
$4,116
Form type
4
Filing time
03 Aug 2021, 18:39:33 UTC
Next filing
22 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TTOO Common Stock Purchase $189 +500 +0.01% $0.38 4.2M 24 Mar 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Sale -$189 -500 -0.01% $0.38 4.2M 24 Mar 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Purchase $557 +600 +0.01% $0.93* 4.2M 25 Mar 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Sale -$557 -600 -0.01% $0.93* 4.2M 25 Mar 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Purchase $490 +1K +0.02% $0.49 4.2M 09 Apr 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Sale -$490 -1K -0.02% $0.49 4.2M 09 Apr 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Sale -$1.38K -2.66K -0.06% $0.52 4.19M 06 May 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Sale -$521 -1K -0.02% $0.52 4.19M 06 May 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Sale -$526 -1K -0.02% $0.53 4.19M 06 May 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Sale -$264 -500 -0.01% $0.53 4.19M 06 May 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Sale -$27 -50 0% $0.53 4.19M 06 May 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Sale -$266 -500 -0.01% $0.53 4.19M 06 May 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Sale -$53 -100 0% $0.53 4.19M 06 May 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Sale -$3.38K -6.26K -0.15% $0.54 4.18M 06 May 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Sale -$55 -100 0% $0.55 4.18M 06 May 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Sale -$517 -939 -0.02% $0.55 4.18M 06 May 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Purchase $14.5K +26.2K +0.63% $0.55 4.21M 06 May 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Sale -$5.76K -10.1K -0.24% $0.57 4.2M 06 May 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Sale -$1.14K -2K -0.05% $0.57 4.2M 06 May 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Sale -$570 -1K -0.02% $0.57 4.2M 06 May 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Purchase $1.37K +2.5K +0.06% $0.55 4.2M 12 May 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Sale -$1.37K -2.5K -0.06% $0.55 4.2M 12 May 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Sale -$166 -200 0% $0.83 4.2M 19 May 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Sale -$2.69K -3.24K -0.08% $0.83 4.19M 19 May 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Sale -$1.69K -2.03K -0.05% $0.83 4.19M 19 May 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Sale -$1.69K -2.03K -0.05% $0.83 4.19M 19 May 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Purchase $8.6K +10.3K +0.25% $0.83 4.2M 19 May 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Sale -$668 -800 -0.02% $0.83 4.2M 19 May 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Sale -$1.7K -2.03K -0.05% $0.83 4.2M 19 May 2020 See Footnotes F1, F2, F3, F4, F5
transaction TTOO Common Stock Purchase $4.12K +5.13K +0.12% $0.80 4.2M 20 May 2020 See Footnotes F1, F2, F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These transactions in the common stock (the "Common Stock") of T2 Biosystems, Inc. (the "Issuer") have not previously been reported on Form 4 and were effected by Goldman Sachs & Co. LLC ("Goldman Sachs") acting as agent on behalf of certain international affiliates that had entered into riskless principal trades in connection with client trade facilitation in the ordinary course of their business.
F2 Without conceding riskless principal trades in connection with client trade facilitation in the ordinary course of business can result in liability under Section 16(b) of the Securities Exchange Act of 1934 (the "Exchange Act"), the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer.
F3 The Reporting Person is a managing director of Goldman Sachs. Goldman Sachs is a subsidiary of The Goldman Sachs Group, Inc. ("GS Group").
F4 GS Group and Goldman Sachs may be deemed to beneficially own indirectly, in the aggregate, 4,157,240 shares of Common Stock of the Issuer by reason of the direct beneficial ownership of Common Stock by certain investment entities (the "GS Funds") because GS Group, or affiliates of GS Group and Goldman Sachs, are the general partner, managing general partner, managing partner, managing member or member of each of the GS Funds. Goldman Sachs beneficially owns directly and GS Group may be deemed to beneficially own indirectly 29,216 shares of common stock.
F5 The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

Remarks:

Balance of trades included in attached schedule. (See Exhibit 99.1)